News | Embolic Protection Devices | October 31, 2017

Distal Filter Embolic Protection Decreases No-reflow Phenomenon in ACS Patients With Attenuated Plaque

Primary endpoint occurred in more than 25 percent of DP patients versus more than 40 percent of patients randomized to conventional treatment

The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the incidence of no-reflow phenomenon after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients with attenuated plaque ≥5mm based upon intravascular imaging. It also examined its long-term effects.

Researchers enrolled 200 ACS patients who had a native coronary artery lesion and attenuated plaque with a longitudinal length of ≥5mm by pre-PCI IVUS. They were randomized to distal filter protection (DP) or conventional treatment (CT).

The primary endpoint of no-reflow phenomenon occurred in 26.5 percent in the DP group (N=98) and 41.7 percent in the CT group (N=96, P=0.0261) and the corrected TIMI frame count after revascularization was significantly lower in the DP group (23 vs. 30.5, P=0.0003). In addition, the incidence of in hospital adverse cardiac events was significantly lower in the DP group than in the CT group (0 percent vs. 5.2 percent, P=0.028).

“The selective use of embolic protection devices for patients at high risk for distal embolization is of great interest among interventional cardiologists,” said Kiyoshi Hibi, M.D., associate professor at Yokohama City University Medical Center in Yokohama, Japan. “VAMPIRE 3 shows that the use of distal embolic protection using a filter device decreased the incidence of no-reflow phenomenon with fewer serious adverse cardiac events after revascularization.”

The VAMPIRE 3 study was funded by Boston Scientific Corp., Nipro and Japan Lifeline. Hibi reported no disclosures.

For more information: www.tctconference.com

Related TCT Content

TCT Announces 2017 Late-breaking Clinical Trial Presentations

Related Content

Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.